Kiora Pharmaceuticals announced the resignation of Chief Development Officer Eric J. Daniels effective April 17, 2026, to pursue another opportunity, with the company initiating a search for his successor.
Key takeaways
Chief Development Officer Eric J. Daniels will resign effective April 17, 2026, to pursue another opportunity.
The resignation did not result from any disagreement regarding the company's operations, policies, or practices.
Kiora has initiated a search for Daniels' successor.
The company states it remains focused on advancing its pipeline of treatments for retinal disease and maintaining momentum across its development programs.
The ABACUS-2 Phase 2 clinical trial (KIO-301) received approval to enroll remaining patients in the 50µg dose cohort and clearance to initiate the 100µg dose cohort.
All planned safety review checkpoints have been cleared in the KLARITY Phase 2 clinical trial (KIO-104), with patient enrollment ongoing.